ObesityWeek 2026
Obesity development is rapidly expanding beyond GLP-1 therapies to include multi-agonists, combination treatments and novel mechanisms. As obesity's impact across cardiovascular, kidney and metabolic (CKM) health becomes increasingly important, sponsors face growing complexity in trial design, patient populations and evidence generation.
At Syneos Health, we combine obesity and CKM expertise with integrated therapeutic, operational, digital and real world evidence capabilities to support development programs from early phase through commercialization.
Meet With Us
Meet with us onsite at booth #300 and meeting suite 5B to discuss how our obesity and CKM experts help sponsors navigate development complexity, optimize trial execution and generate the evidence needed to advance innovative obesity therapies across the CKM continuum and related conditions.
Related Content
Looking for exclusive insight?
